{"prompt": "['Neurological: paralysis, temporary weakness or numbness in legs, dysesthesias or allodynia', 'Hypersensitivity reactions to the medications used during the procedure (e.g. anesthetic, or', 'sedative): respiratory or cardiac reactions, seizures, allergic reaction, serious and occasional', 'fatal hypersensitivity (anaphylactic) reactions', 'Endocrine: short-term increases in blood glucose levels may occur with one-time administration', 'of corticosteroid, in patients with diabetes', 'Infection', 'Cardiovascular: bleeding at the incision site, injury to blood vessels, clotting of veins', 'Vasovagal reaction, hypotension (low blood pressure) (these occur only intra-procedure or', 'immediately after the procedure)', 'Miscellaneous: Swelling and bruising at the incision site', 'Anticipated AEs following prolonged fluoroscopy (X-ray) might include: hair loss, skin redness,', 'and skin damage.', 'A serious adverse event (SAE) is defined as any untoward medical occurrence that:', 'Results in death', 'Is life-threatening (Note: the term life-threatening in the definition of \"serious\" refers to an event in', 'which the patient was at risk of death at the time of the event; it does not refer to an event which', 'hypothetically might have caused death if it were more severe).', 'Requires inpatient hospitalization or prolongation of existing hospitalization.', 'Results in persistent or significant disability/incapacity.', 'Results in congenital anomaly/birth defect (if exposure to a medical product prior to conception', 'or during pregnancy may have resulted in an adverse outcome in the child).', 'Requires intervention to prevent permanent impairment or damage.', 'Important medical events that may not result in death, be life-threatening or require', 'hospitalization may be considered a SAE when, based on appropriate medical judgment, they', 'may jeopardize the patient and may require medical or surgical intervention to prevent one of the', 'outcomes listed in this definition.', 'In the proposed trial, the following events are considered SAEs:', 'Neurologic: paralysis, stroke, central nervous system infection', 'Serious hypersensitivity: anaphylactic reactions', 'Death', 'An event that is life threatening, is permanently disabling, or requires inpatient hospitalization', 'Severity of adverse event grading scale:', 'Mild: an experience that is usually transient, and requires no special treatment or intervention', 'Moderate: an experience that is alleviated with simple therapeutic treatments', 'Severe: an experience that requires more than simple therapeutic interventions', 'Relationship to research participation AEs:', 'Unrelated - This causal relationship is assigned when the AE is definitely not associated with the', 'research participation/treatment', 'Unlikely - This causal relationship is assigned when there is no temporal relationship to the', 'administration of the investigational material or other factors are more likely to have caused the', 'VA Puget Sound IRB Protocol Template - Version 1.0: 04/2018', 'Page 49 of 55', 'VA Puget Sound IRB Approved', '03/12/2020']['event.', 'Possibly related - This causal relationship is assigned when the AE starts at a reasonable time', \"after study participation but could have been produced by the subject's clinical state or other\", 'modes of therapy administered to the subject.', 'Probably related - This causal relationship is assigned when the adverse event starts at a', 'reasonable time after study participation, stops/improves when study participation/treatment has', 'been stopped, and cannot be reasonably explained by known characteristics of the clinical state.', 'Definitely related - This causal relationship is assigned when the adverse event starts at a', 'reasonable time after study participation/treatment, stops/improves when study', 'participation/treatment has been stopped, can reasonably be explained by known characteristics', 'of the study participation/treatment.', 'B. Determination of an Adverse Event', 'AE identification', \"We will monitor for adverse events during the entire duration of each patient's participation, including all\", 'scheduled/completed monthly assessments and reporting offered by participants during unplanned', 'contacts. In the proposed trial, there are two methods for AE identification: active and passive.', 'Active identification', 'Patient Reported: At scheduled study assessments, research staff will inquire about medical/adverse', 'events including surgery, ED visits, hospitalizations and ICU admissions, and allergic reactions. When', 'a patient reports any of the medical events listed above, study research staff will complete an Adverse', 'Event form (Attachment V - Adverse Event Form) and ask the patient details about the event. Such', 'information will include, at a minimum, the date of the event, event seriousness, event treatment and', 'event outcome. Assessments of AEs will include an open-ended question: \"Did you experience any', 'other complications?\" We will treat any response to these questions as if it is an AE until the study PI', 'can further review and discuss it with the study team if needed.', 'Passive identification', 'Medical records review: We will monitor medical records for SAEs at the time of scheduled', 'assessments (monthly) until the end of the 3-month data collection, or longer if a participant elects to', 'continue with optional study assessments after 3 months. If we identify an SAE, the study coordinator', 'will complete an AE CRF and inform the study Pl. The list of SAEs to be checked for monthly include: a', 'major neurologic event (paralysis, stroke, central nervous system infection), serious hypersensitivity/', 'anaphylactic reactions, death, a life-threatening or permanently disabling event, or one that requires', 'inpatient hospitalization.', 'AE attribution and outcome', 'The study PI will review all AEs to determine study relatedness and outcome of the event. If the PI is', 'not available, AEs that are more pertinent to medical issues or procedures will be reviewed by Dr.', 'Nishio or Soares, and AEs that are more pertinent to mental health will be reviewed by Dr. Williams.', 'VA Puget Sound IRB Protocol Template - Version 1.0: 04/2018', 'Page 50 of 55', 'VA Puget Sound IRB Approved', '03/12/2020']\n\n###\n\n", "completion": "END"}